Related Experiment Video
Updated: May 7, 2026
Catalytic Scavenging of Plant Reactive Oxygen Species In Vivo by Anionic Cerium Oxide Nanoparticles
Published on: August 26, 2018
Recent Advances in ROS-Scavenging Metallic Nanozymes for Anti-Inflammatory Diseases: A Review
Adityanarayan Mohapatra1, In-Kyu Park1
1Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju, Korea.
Abstract:
Oxidative stress and dysregulated inflammatory responses are the hallmarks of inflammatory disorders, which are key contributors to high mortality rates and impose a substantial economic burden on society. Reactive oxygen species (ROS) are vital signaling molecules that promote the development of inflammatory disorders. The existing mainstream therapeutic approaches, including steroid and non-steroidal anti-inflammatory drugs, and proinflammatory cytokine inhibitors with anti-leucocyte inhibitors, are not efficient at curing the adverse effects of severe inflammation. Moreover, they have serious side effects. Metallic nanozymes (MNZs) mimic the endogenous enzymatic process and are promising candidates for the treatment of ROS-associated inflammatory disorders. Owing to the existing level of development of these metallic nanozymes, they are efficient at scavenging excess ROS and can resolve the drawbacks of traditional therapies. This review summarizes the context of ROS during inflammation and provides an overview of recent advances in metallic nanozymes as therapeutic agents. Furthermore, the challenges associated with MNZs and an outline for future to promote the clinical translation of MNZs are discussed. Our review of this expanding multidisciplinary field will benefit the current research and clinical application of metallic-nanozyme-based ROS scavenging in inflammatory disease treatment.
Insights
Metallic nanozymes (MNZs) offer a promising solution for inflammatory disorders by effectively scavenging reactive oxygen species (ROS). These nanozymes overcome the limitations and side effects of traditional treatments, paving the way for improved therapeutic strategies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Inflammation Research
Background:
- Inflammatory disorders are characterized by oxidative stress and inflammation, contributing to high mortality and economic burden.
- Reactive oxygen species (ROS) play a crucial role in the pathogenesis of inflammatory diseases.
- Current treatments for severe inflammation, including steroids and cytokine inhibitors, have limited efficacy and significant side effects.
Purpose of the Study:
- To review the role of ROS in inflammation.
- To summarize recent advancements in metallic nanozymes (MNZs) as therapeutic agents for ROS-associated inflammatory disorders.
- To discuss challenges and future directions for the clinical translation of MNZs.
Main Methods:
- Literature review focusing on ROS in inflammation.
- Analysis of recent research on metallic nanozymes (MNZs) for ROS scavenging.
- Discussion of therapeutic potential and clinical translation hurdles for MNZs.
Main Results:
- Metallic nanozymes (MNZs) effectively scavenge excess ROS, mimicking endogenous enzymatic activity.
- MNZs demonstrate potential to overcome the limitations and side effects associated with conventional anti-inflammatory therapies.
- Recent advances highlight MNZs as promising therapeutic candidates for inflammatory diseases.
Conclusions:
- Metallic nanozymes (MNZs) represent a novel and effective strategy for managing oxidative stress in inflammatory conditions.
- Further research and development are crucial to address challenges and facilitate the clinical application of MNZs in treating inflammatory diseases.
- This review provides a comprehensive overview to guide future research and clinical translation of MNZ-based therapies.
